Q1 2026 · 13F-HR
GSK plc (GSK, GLAXF)holdings as filed
Filed 2026-05-14 · accession 0001999371-26-010742
$599.2M
Reported value
13
Positions
2026-03-31
Period end
The Brief · GSK plc (GSK, GLAXF) · Q1 2026
AI · grounded in 13F
GSK plc closed its position in Senseonics Hldgs Inc SENS, reducing its holdings by $59,925. The fund also exited its position in Harvard Bioscience Inc HBIOUSD for a total of $7,458. These two divestments represent the only changes to a portfolio consisting of 13 positions with a total AUM of $599,153,380.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| H17182108 | CRSP | CRISPR THERAPEUTICS AG | $153.2M | 25.6% | 3,220,627 | Common | SOLE |
| Y95308105 | WVE | WAVE LIFE SCIENCES LTD | $132.3M | 22.1% | 18,245,691 | Common | SOLE |
| 09075V102 | BNTX | BIONTECH SE | $79.1M | 13.2% | 889,824 | Common | SOLE |
| 92764N102 | VIR | VIR BIOTECHNOLOGY INC | $76.6M | 12.8% | 8,550,954 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $44.4M | 7.41% | 1,333,333 | Common | SOLE |
| 55083R203 | LYEL | LYELL IMMUNOPHARMA INC | $30.3M | 5.06% | 1,512,659 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $22.4M | 3.74% | 340,434 | Common | SOLE |
| 84833T103 | SPRO | SPERO THERAPEUTICS INC | $21.5M | 3.59% | 9,190,606 | Common | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $13.7M | 2.29% | 1,785,714 | Common | SOLE |
| 126638105 | CVRX | CVRX INC | $9.5M | 1.59% | 1,007,583 | Common | SOLE |
| 088786108 | BCYC | BICYCLE THERAPEUTICS PLC | $7.1M | 1.18% | 1,529,561 | Common | SOLE |
| 65487U108 | NKTX | NKARTA INC | $6.6M | 1.11% | 3,150,732 | Common | SOLE |
| 75901B107 | RGNX | REGENXBIO INC | $2.3M | 0.38% | 271,456 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.